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ABSTRACT Some tumor cells contain mutant ras genes
that are capable of transforming NIH 3T3 cells. Those genes
that have been analyzed arise from the wild-type, non-trans-
forming ras genes by mutations producing single amino acid
substitutions at position 12 or 61 of the encoded protein. We
have performed random bisulfite-induced mutagenesis on the
cloned wild-type human H-ras gene to find if mutations at oth-
er positions can activate the transforming potential of that
gene. Most mutations are not activating, but mutations that
specify single amino acid substitutions at position 12, 13, 59, or
63 of the encoded protein do activate the transforming poten-
tial of the H-ras gene. Some, but not all, mutant ras proteins
show an altered electrophoretic mobility in NaDodSO4/poly-
acrylamide gels.
The ras genes are members of a highly conserved family of
vertebrate genes first detected as the oncogenes of Harvey
and Kirsten sarcoma viruses (1). They encode immunologi-
cally cross-reactive, guanine nucleotide binding proteins of
-21,000 daltons (2). There are at least three human ras
genes, H-, K-, and N-ras, which encode four distinct ras
peptides of 188 or 189 amino acids, identical in sequence for
the first 86 positions (3-5). Mutated ras genes have been de-
tected in some human tumor cells by the ability of tumor cell
DNA to induce tumorigenic transformation in NIH 3T3 cells
upon DNA-mediated gene transfer. To date, many activating
mutations of ras genes from human tumor cells have been
analyzed and they all specify amino acid substitutions at po-
sition 12 or 61 of the encoded protein (3-11). To determine
whether other mutations of the ras genes could also activate
the transforming potential of the wild-type normal genes, we
tested the transforming capacity of randomly mutagenized
wild-type H-ras genes.
MATERIALS AND METHODS
Cells, Transfections, and Immunoprecipitations. NIH 3T3
cells were cultured and transfected as described (12). Mor-
phologically altered foci were scored 18 days after DNA
transfer. Escherichia coli strains were MM294 (r-m+, rec+)
for routine plasmid growths and BD1528 (ung-) (the gift of
D. Shortle) was used only for transfection of DNA after bi-
sulfite mutagenesis. E. coli transfections were performed as
described (13). Cell labeling and immunoprecipitations were
performed as described (14).
Plasmid DNAs and Sequencing. The plasmid pT24 con-
tained the transforming H-ras gene of T24 bladder carcinoma
cells, encoding valine in position 12 (8, 15). The plasmid pP3
contained the wild-type human H-ras gene, encoding glycine
in position 12, cloned initially from human placenta (8). The
plasmid pTPT differs from pT24 only in containing the 242-
base-pair (bp) Mst II/Xba I fragment of the wild-type H-ras
gene contained in pP3. Its map is shown in Fig. 1. It there-
fore encodes glycine in position 12 and a normal H-ras pro-
tein. The plasmid EMS9 differs from pT24 in that it lacks any
intron after the first coding exon. It was constructed by us-
ing the plasmids RC3 and RC6 containing cDNAs of the H-
ras transcript (15). The protein it encodes also contains
valine in position 12. The plasmid EMSH3 differs from
EMS9 in that it contains the 34-bp Hae II/Pvu II fragment of
the viral Harvey ras gene (16), cloned into the corresponding
Hae II/Pvu II site of plasmid EMS9. It therefore encodes
arginine in position 12. Clones of bisulfite-mutagenized
pTPT were initially grown in ung- BD1528 and then trans-
fected into MM294 for large-scale growth. DNA restriction
endonuclease fragments from the mutagenized regions were
subcloned into the original pTPT plasmid and grown in
MM294. Plasmid DNAs for DNA sequencing or transfection
of animal cells was prepared by either of two methods.
Large-scale individual plasmid DNAs were prepared from
one-liter cultures of MM294 by the method of detergent lysis
and CsCl/ethidium bromide banding (17). DNAs from ung-
E. coli containing mutagenized plasmids were made on 5-ml
saturated cultures by previously published methods (18).
DNA sequencing was performed according to Maxam and
Gilbert (19) by using the strategy published previously (15).
Sodium Bisulfite Mutagenesis of Doubly Gapped, Circular
pTPT Molecules. For mutagenesis of the ras gene coding re-
gions, supercoiled pTPT DNA (20 ,ug in a 200-,ul reaction
volume) was digested to completion with pairs of restriction
endonucleases. To mutagenize the region encoding amino
acids 1-37, EcoRI and Xba I were used. To mutagenize the
region encoding amino acids 38-110, Xba I and Nco I were
used (see Fig. 1). At the end of the incubation, 20 ,ul of 0.25
M Na2EDTA and 13 ,ul of 4.5 M NaOH were added to each
reaction tube. After 5 min at room temperature, 1 ml of dis-
tilled water, 20 ,ul of 30% Ficoll 400, 0.02% bromophenol
blue, and 40 mM EDTA were added, and the resulting solu-
tion was loaded into a 150 x 2 x 8 mm empty slot of a hori-
zontal-wick 1% agarose gel at room temperature. After com-
plete filling of the slot with distilled water, the gel was cov-
ered with SaranWrap and run at 80 V. The buffer system
used was 40 mM Tris acetate, pH 7.9/4 mM sodium ace-
tate/1 mM EDTA (TNE buffer). The location of the single
strands was determined by ethidium bromide staining. Gel
slices containing the fast- and slow-moving strands from the
high molecular weight fragment of the above digested DNA
were combined, respectively, with gel slices containing the
slow and fast moving strands of the high molecular weight
fragment of pTPT cleaved with Bgl II and Sal I, prepared in
the same manner. The pairs of gel slices containing comple-
Abbreviations: kbp, kilobase pair(s); bp, base pair(s).
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mentary DNA strands were electroeluted together in TNE
buffer for 12 hr at 80 V. To the resulting solution (-20 ml), 2
ml of 1 M Tris-HCl (pH 7.5), 2 ml of5 M NaCl, and 0.2 ml of
0.25 M EDTA were added, and any insoluble material was
removed by centrifugation in 50-ml Falcon tubes at 1800 x g
for 15 min. Circular, partially single-stranded plasmid DNA
was formed by immersion of the 50-ml Falcon tubes contain-
ing the above described solution in a 1-liter bath that was
allowed to warm up to 760C on a heating plate. After 10 min
at this temperature, the plate was switched off and the solu-
tion was allowed to cool slowly to room temperature. After
addition of 200 Ag of tRNA and 2 vol of ethanol, the solution
was kept for 12 hr at -80'C and then centrifuged at 25,000
rpm in siliconized polyallomer tubes for 30 min at 40C in a
SW 27 rotor. The plasmid DNA pellet was resuspended in
200 pd of 1.5 mM sodium citrate, pH 7.0/15 mM NaCl and
treated with 3 M bisulfite for 10 min at 370C as described by
Shortle and Nathans (20). After ethanol precipitation, muta-
genized and gapped DNA was dissolved in 50 kd of 10 mM
Tris HCl, pH 7.5/1 mM EDTA. ung- E. coli was then trans-
formed by the gapped and mutagenized DNA. We obtained
from 200 to 2000 ampicillin-resistant colonies per ug of
DNA. Ampicillin-resistant colonies were handled as de-
scribed in the text. The extent of bisulfite mutagenesis was
monitored both by the loss of restriction endonuclease sites
and DNA sequence analysis of randomly selected mutagen-
ized plasmids. By this method we detected no unmutagen-
ized plasmids.
Oligonucleotide Screening of Mutants. Oligonucleotides
were synthesized by the modified phosphate triester method
(21) using a BIOSEARCH SAM DNA synthesizer and were
purified by electrophoresis in a 20% acrylamide/8 M urea
gel. Oligonucleotide screening of bacterial colonies contain-
ing the mutant plasmids was done as described by Wallace et
al. (22).
RESULTS
Sodium bisulfite treatment of plasmid DNA containing a sin-
gle-stranded gap will induce the chemical conversion of
deoxycytidine into deoxyuridine residues preferentially in
the single-stranded region (20, 23). The extent of this reac-
tion can be controlled by time and bisulfite concentration.
After treatment, introduction of the plasmid DNA into ung-
E. coli, lacking deoxyuridine N-glycosidase, results in gap
repair and replication with the final result that some C-G
pairs are converted to T-A pairs. We treated in this manner a
clone of the human H-ras gene that encodes a normal ras
protein in order to introduce random mutations in coding re-
gions. Single-stranded gaps were introduced as shown in
Fig. 1. Two regions were mutagenized separately: region I,
2.3 kilobase pairs (kbp) spanning EcoRI to Xba I; and region
II, 509 bp spanning Xba I to Nco I. Both coding and noncod-
ing strands were mutagenized. As a result, 25 codons in re-
gion I, encoding the first 37 amino acid positions, and 51
codons in region II, encoding amino acid positions 38-110,
could be mutagenized, including the 12th but not the 61st
codons.
Gapped plasmids were treated so that on average 1 deoxy-
cytidine residue per 30 was altered. After transformation of
ung E. coli, several hundred colonies of ampicillin-resistant
E. coli were individually picked and grouped into pools of 10
colonies each. Plasmid DNA was prepared from each pool of
10 and tested for the ability to induce the typical foci of mor-
phologically altered NIH 3T3 murine fibroblasts that we as-
sociate with mutated ras genes that have transforming ca-
pacity. Plasmid DNAs were then individually tested from
pools that were positive. The vast majority of plasmids wasincapable of transforming NIH 3T3 cells (see below), from
which we conclude that most mutations do not activate the
transforming potential of the ras genes.
Four of 40 pools of plasmids mutagenized in region I were
positive. From these pools, five mutants were found that
could efficiently transform NIH 3T3 cells. These five were
analyzed further. First, the 242-bp Mst II/Xba I fragment
containing the entire first coding exon was purified from mu-
tants and ligated with the 2.0-kbp EcoRI/Mst II and 8.5-kbp
Xba I/EcoRI fragments of the H-ras gene contained on
pTPT (see Materials and Methods) to create a chimeric
gene. These chimeric genes were also active in the NIH 3T3
transformation assay (see Table 1), indicating that the acti-
vating mutation was contained on the 242-bp Mst II/Xba I
fragment. The coding sequences of the mutagenized region
were then sequenced. All five mutants encoded proteins
with single amino acid substitutions at either position 12 or
13, with serine or aspartic acid replacing glycine.
A similar protocol was followed for mutants of region II.
Twenty pools of 10 colonies each were screened and 2 were
positive. From these, two individual plasmid clones with
transforming activity were identified. The 509-bp Xba I/Nco
I fragment from these was ligated with the 2.3-kb Eco-
RI/Xba I and 7.9-kbp Nco I/EcoRI fragments of the H-ras
gene contained on pTPT to create chimeric genes. The activ-
ity of the resulting chimeras was tested in transfection assays
(see Table 1). Finally, the coding sequences contained on the
509-bp Xba I/Nco I fragment were sequenced. The first mu-
tant with transforming activity we analyzed encoded a pro-
tein with a single amino acid substitution: lysine for glutamic
acid at position 63. The second mutant encoded a protein
with four amino acid substitutions: lysine for glutamic acid at
position 49, threonine for alanine at position 59, lysine for
glutamic acid at position 62, and histidine for arginine at po-
sition 73.
Since the substitution of threonine for alanine in position
59 is also found in the ras genes of the Harvey and Kirsten
sarcoma viruses, we were interested in determining if this
mutation alone sufficed to activate the transforming poten-
tial of ras genes. To this end, we synthesized an oligonucleo-
tide, T-G-G-C-C-G-G-T-G-G-T-A-T-C-C, which is comple-
mentary to the sequence of the mutant encoding a threonine
substitution, and used this as a probe to isolate threonine
substitution mutants among a larger population of plasmids
mutagenized in region II. Eight were isolated. Including the
previous threonine mutant, at least four of nine mutants
were unique, as judged by the pattern of loss of restriction
endonuclease sites in the mutagenized region. Seven of the
eight new mutants had transforming activity when tested on
NIH 3T3 cells. One of these was sequenced, and it too con-
tained multiple amino acid substitutions: arginine for lysine
at position 42, asparagine for aspartic acid at position 47, and
methionine for valine at position 81, in addition to threonine
for alanine at position 59. However, since seven of eight ran-
domly picked threonine substitution mutants efficiently
transformed NIH 3T3 cells and since most mutations do not
activate the ras gene, we conclude that it is highly probable
that substitution of threonine for alanine in position 59 is suf-
ficient to activate the transforming potential of the ras genes.
We measured the transforming capacity of our chimeric
genes in NIH 3T3 focus assays. For comparison, we utilized
the pT24 plasmid specifying valine for glycine in position 12.
We also included in this survey an H-ras gene we construct-
ed specifying another single amino acid substitution at posi-
tion 12: arginine for glycine. This was made by recombining
in vitro the wild-type human H-ras gene with the Harvey
sarcoma virus ras gene that encodes arginine at position 12
(see Materials and Methods). The efficiency of transforma-
tion of the various mutants varied considerably. The differ-
ences we observed between mutants were reproducibly ob-
tained in independent experiments but may not be biological-
ly significant since we have not excluded the existence of
additional mutations within introns.
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FIG. 1. The scheme for H-ras mutagenesis. Shown at the top is the structure of the plasmid pTPT containing a nontransforming human H-
ras gene as a 6.5-kbp BamHI insert in pBR322. Restriction endonuclease sites shown are EcoRI, E; BamHI, B; Mst II, M; Xba I, X; Nco I, N;
Bgl 11, Bg; and Sal I, S. The restriction map is complete except for Mst 11. There is one Mst 11 site only in the 2.0-kbp EcoRI/Xba I fragment,
but there are multiple sites in the 4.6-kbp Xba I/BamHI fragment. The above restriction map is not to scale, but distances between restriction
endonuclease sites are indicated in kbp. Filled boxes indicate coding exons. The empty box indicates the pBR322 13-lactamase gene. Shown
below is the scheme for creating a plasmid with a single-strand gap exposing either strand of region II.
It was of interest to observe the transforming capacity of
genes with double mutations. To this end, we recombined
genes with mutations in region II with the gene encoding
valine at position 12. The resulting double mutants were test-
ed in NIH 3T3 cells (see Table 1). Mutants encoding valine at
position 12 and threonine at position 59 had an efficiency of
transformation that was intermediate between either paren-
tal mutant. By contrast, the mutant gene encoding valine at
position 12 and lysine at position 63 had a lower transforma-
tion efficiency than either parental mutant gene, suggestive
that there may be interference between these two mutations.
Mutant ras proteins can have altered electrophoretic mo-
bility. The H-ras protein of T24 bladder carcinoma cells,
containing a valine substitution at position 12, runs slower
than wild-type protein in NaDodSO4/polyacrylamide gels
(6), as does the K-ras protein of Calu-1 lung carcinoma cells
(24), which contains a cysteine substitution at position 12 (4,
5). On the other hand, the N-ras protein of SK-N-SH neuro-
blastoma cells, which contains a lysine substitution in posi-
tion 61 (3), runs more rapidly than expected (25). To explore
whether this is a general property, we examined the electro-
phoretic mobility of our mutant proteins in NaDodSO4/
polyacrylamide gels (see Fig. 2). Like the mutant H-ras pro-
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Table 1. Amino acid changes that activate the transforming
potential of the normal H-ras gene
Amino acid at positions in Relative potency
the H-ras-encoded p21 in focus
Plasmid 12 13 59 63 induction
pP3 (negative
control) Gly Gly Ala Glu <0.0001
pTPT (negative
control) Gly Gly Ala Glu <0.0001
pT24 (positive
control) Val Gly Ala Glu 1.0
EMSH3 Arg Gly Ala Glu 0.6*
BSS176t Asp Gly Ala Glu 0.5
BSS194 Ser Gly Ala Glu 0.4
BSS180 Gly Asp Ala Glu 0.2
BSC454 Gly Asp Ala Glu 0.2
BSS197 Gly Ser Ala Glu 0.001
TP024t Gly Gly Ala Lys 0.1
TT024t Val Gly Ala Lys 0.05
TP087t Gly Gly Thr Glu 0.2
TT087f Val Gly Thr Glu 0.8
THRO9§ Gly Gly Thr Glu 0.6
Plasmids pP3, pT24, pTPT, and EMSH3 are described in Materi-
als and Methods. All others derive from pTPT and contain only
point mutations. With the exception of EMSH3 (see footnote *), all
transforming potencies are relative to that of pT24 in a standard fo-
cus-induction assay. At least two assays were performed on each
plasmid. The encoded amino acids that differ from the wild type are
shown in italics.
*The potency of EMSH3 is relative to that of the corresponding
cloned intronless gene (EMS9) encoding valine in position 12. The
potency of EMS9 relative to that of pT24 was about 0.05.
tAn additional silent mutation (G-to-A transition) was present in the
third position of the codon corresponding to valine in position 7
(BSS176) and glutamic acid in position 76 (TP024 and 1T024).
tAdditional mutations leading to amino acid change were present in
positions 49 (lysine instead of glutamic acid), 62 (lysine instead of
glutamic acid), and 73 (histidine instead of arginine).
§Additional amino acid changes were present in positions 42 (argi-
nine instead of lysine), 47 (asparagine instead of aspartic acid), and
81 (methionine instead of valine). The change in position 42 was the
result of an A-to-G transition; all the other mutations were G-to-A
transitions.
mutant protein containing arginine in this position (lane k)
migrates more slowly than wild-type protein (lanes c, h, and
m). The mutant protein encoded by Harvey sarcoma viral
ras containing both arginine in position 12 and threonine in
position 59 migrates even more slowly (lane 1, lower band;
the upper band corresponds to the form phosphorylated on
threonine at residue 59). A very minor decrease in electro-
phoretic mobility is seen also for proteins containing serine
in position 12 or 13 (lanes d and e) and possibly for proteins
containing aspartic acid in position 13 (lane g), whereas no
change is observed for proteins containing aspartic acid in
position 12 (lane f). Mutant ras proteins with alterations in
this region thus either have the same or a decreased electro-
phoretic mobility compared to wild type. On the other hand,
like the N-ras protein SK-N-SH, mutant proteins containing
a substitution in region II (lysine 63, lane i, or a quadruple
mutant including threonine 59, lane j) have an increased elec-
trophoretic mobility.
Both the Harvey and Kirsten sarcoma viral ras proteins
have a threonine residue at position 59 in place of the alanine
residue encoded by wild-type ras genes (16, 26). This residue
is the site of phosphorylation of the viral proteins (27). In
contrast, the wild-type H-ras protein is phosphorylated only
at very low levels at one or more seine residues (2). We
have found that all of the mutant ras proteins containing
threonine at position 59 are phosphorylated efficiently in
a b c d e f g h j k m
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FIG. 2. NIH 3T3 cells transformed with the indicated H-ras
genes were labeled with [35S]methionine for 16 hr at 370C and then
incubated for 1 hr in complete medium, to permit post-translational
processing of labeled polypeptides (14). Cell extracts were immuno-
precipitated with anti-ras monoclonal antibody Y13-238 (14). Immu-
noprecipitates (14) were electrophoresed through a 4% polyacryla-
mide stacking gel and a 30-cm-long 12% polyacrylamide resolving
gel as described (32), and radioactive bands were visualized by fluo-
rography. For ease of comparison, samples were approximately nor-
malized for amount of precipitated H-ras protein. Lane a, immuno-
precipitate from NIH 3T3 cells. Lanes b-k and m, immunopre-
cipitates from NIH 3T3 cells transfected with human H-ras
containing the indicated amino acid substitutions. Lanes: b, valine
at position 12; c, wild type; d, serine at position 12; e, serine at
position 13; f, aspartic acid at position 12; g, aspartic acid at position
13; h, wild type; i, lysine at position 63; j, lysine at position 49,
threonine at position 59, lysine at position 62, and histidine at posi-
tion 73; k, arginine at position 12; m, wild type. Lane 1, immunopre-
cipitate from NIH 3T3 cells transfected with the Harvey sarcoma
viral ras gene. The arrow on right indicates the position of wild-type
human H-ras protein. Arrows on left indicate positions of 14C-la-
beled molecular weight markers (Bethesda Research Laboratories):
,-lactoglobulin (Mr 18,400) and a-chymotrypsinogen (M, 25,700).
vivo (data not shown). It is highly probable that this modifi-
cation occurs at threonine 59 and results from autophospho-
rylation using GTP as substrate, as has been shown for the
viral ras proteins (2, 27, 28). We conclude that transforming
mutations affecting residue 12 are not required and that thre-
onine 59 alone suffices for efficient phosphorylation of the
H-ras protein.
DISCUSSION
Transforming genes have been found in RNA tumor viruses
and in tumor cells. In general, they derive from normal cellu-
lar genes by a variety of complex processes: translocation,
transduction, deletion, fusion, and point mutation (29). The
clearest examples are the transforming ras genes, which dif-
fer from normal ras genes by a single point mutation result-
ing in a single amino acid substitution of the encoded protein
(3-11).
In our present study we have utilized random bisulfite mu-
tagenesis, a generally applicable procedure, for finding point
mutations that can activate the transforming potential of a
normal gene. We have not conducted an exhaustive study.
We have not, for example, mutagenized the 3' one-third of
the H-ras gene, and we have probably not assessed all of the
possible bisulfite-inducible mutations even in the regions we
did mutagenize. There are intrinsic limits to the bisulfite mu-
tagenesis: not all positions can be mutated and of those that
can, only a circumscribed set of nucleotide changes can re-
sult. Moreover, recent work from our laboratory (unpub-
lished) indicates that not all cytosine residues in a single-
stranded region are equally likely to be modified by bisulfite
treatment. Nevertheless, the rate-limiting step in endeavors
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of this kind is not the number and variety of mutants but
their screening and analysis. For this reason, a method of
mutagenesis that always introduced just single random muta-
tions in the mutagenized DNA would be preferable.
We have found an interesting set of new transforming mu-
tants. Not only can any of several mutations of the 12th and
61st codons activate the transforming potential of the ras
genes, a conclusion that comes from previous studies, but
also mutations of the 13th and 63rd codons can, and, very
probably, mutations of the 59th codon as well. Tabin et al.
(6) first noted that ras p21 with valine substituting glycine in
position 12 had altered electrophoretic mobility in NaDod-
S04/polyacrylamide gels. Computer predictions have indi-
cated that any amino acid substitution for glycine in position
12 could drastically alter ras p21 conformation by extending
the protein from its normally compact form (30), consistent
with the observed shifts in electrophoretic mobility of mu-
tant p2is. Our data indicate that some, but not all, amino
acid substitutions at positions 12 and 13 that have drastic
effects on ras p21 function can significantly alter protein mo-
bility in NaDodSO4/polyacrylamide gels. Our data also indi-
cate that amino acid substitutions in the region about posi-
tions 59-63 also greatly alter p21 mobility. These observa-
tions are consistent with the idea that the amino acid
substitutions that activate ras p21 do so by disrupting protein
structure, thereby disrupting some critical protein function.
We argue that the region about positions 59-63 neighbors
the GTP binding site of the ras proteins, since when threo-
nine is encoded in position 59, it is a site for autophospho-
rylation by GTP (27). Others have argued that region about
amino acids 12 and 13 may neighbor the ras GTP binding
site, since this region has amino acid homology to known
nucleotide binding proteins (31). If indeed activating muta-
tions occur near the guanine nucleotide binding site, this
binding must be relevant to the physiologic function of the
ras protein. For example, there may be two conformational
isomers of ras p21, induced upon binding of GTP and/or
GDP, in which only one of the isomers can stimulate cell
growth. The high binding affinity of both nucleotides for ras
p21 is in accord with their role as conformational effectors
rather than substrates in the usual sense (2, 27, 28). If this
line of thinking is correct, the activating mutations might
lead to altered conformational properties of the p21 nucleo-
tide complexes either by disrupting conformational changes
induced by interaction with guanine nucleotides or by dis-
rupting the interaction between p21 and another protein that
might in turn regulate guanine nucleotide binding.
Although amino acid substitutions at positions 13, 59, and
63 appear to activate the transforming potential of the ras
protein as assayed on NIH 3T3 cells, to date all mutations of
ras genes from human tumor cells that have been analyzed
specify amino acid substitutions at position 12 or 61 (3-11).
This discrepancy may have a biological basis. As a partial
explanation, not all mutations may be equally effective at
inducing tumorigenic transformation, and our data are con-
sistent with this. For example, the mutant encoding serine in
place of glycine at position 13 is particularly weakly trans-
forming. A second problem is raised by the observation that
the ras genes contained on Harvey and Kirsten sarcoma vi-
ruses each have at least two activating mutations. The Har-
vey sarcoma virus ras gene encodes arginine at position 12
and the Kirsten sarcoma virus ras gene encodes serine at this
position, while both encode threonine at position 59 (16, 26).
Yet, the present study indicates that any one of these muta-
tions is sufficient to strongly activate ras. We can offer no
simple explanation for this at present.
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